Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose‐ranging safety study

Allergen‐specific immunotherapy (SIT) with native allergen extracts and allergoids has been performed successfully for decades. Preliminary studies revealed the use of recombinant allergen‐preparations as a promising option for SIT.

[1]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy , 2012, Clinical and Translational Allergy.

[2]  M. Rottem.  [Allergic rhinitis and its impact on asthma]. , 2010, Harefuah.

[3]  S. Durham,et al.  Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. , 2008, The Journal of allergy and clinical immunology.

[4]  I. Swoboda,et al.  Different allergenic activity of grass pollen allergens revealed by skin testing , 2008, European journal of clinical investigation.

[5]  K. Bergmann,et al.  Specific Immunotherapy for Common Grass Pollen Allergies: Pertinence of a Five Grass Pollen Vaccine , 2008, International Archives of Allergy and Immunology.

[6]  R. G. Das,et al.  EU Forum: The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantification , 2008, Allergy.

[7]  S. Vrtala.  Review article: From allergen genes to new forms of allergy diagnosis and treatment , 2008, Allergy.

[8]  M. Ventura,et al.  Local and Systemic Reactions Occurring During Immunotherapy: An Epidemiological Evaluation and a Prospective Safety-Monitoring Study , 2008 .

[9]  A. Sheikh,et al.  Allergen injection immunotherapy for seasonal allergic rhinitis. , 2007, The Cochrane database of systematic reviews.

[10]  J. Bousquet,et al.  Standards for practical allergen‐specific immunotherapy , 2006, Allergy.

[11]  H. Fiebig,et al.  Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. , 2006, Immunology and allergy clinics of North America.

[12]  S. Durham,et al.  Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. , 2006, The Journal of allergy and clinical immunology.

[13]  M. Jutel,et al.  Allergen-specific immunotherapy with recombinant grass pollen allergens. , 2005, The Journal of allergy and clinical immunology.

[14]  A. Narkus,et al.  Efficacy and safety of preseasonal‐specific immunotherapy with an aluminium‐adsorbed six‐grass pollen allergoid , 2005, Allergy.

[15]  S. Durham,et al.  Prevalence and rate of diagnosis of allergic rhinitis in Europe , 2004, European Respiratory Journal.

[16]  C. L. Hardy,et al.  Blocking antibodies in allergen immunotherapy: the Yin and Yang , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[17]  S. Durham,et al.  Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity1 , 2004, The Journal of Immunology.

[18]  H. Fiebig,et al.  Transition of recombinant allergens from bench to clinical application. , 2004, Methods.

[19]  S. Durham,et al.  Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.

[20]  G. Roberts,et al.  Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. , 2003, The Journal of allergy and clinical immunology.

[21]  J. Lidholm,et al.  Characteristics and Immunobiology of Grass Pollen Allergens , 2003, International Archives of Allergy and Immunology.

[22]  P. Eng,et al.  Long‐term efficacy of preseasonal grass pollen immunotherapy in children , 2002, Allergy.

[23]  Erkka Valovirta,et al.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.

[24]  N. York,et al.  Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study. , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  C. Traube,et al.  Immunotherapy with a calcium phosphate‐adsorbed five‐grass‐pollen extract in seasonal rhinoconjunctivitis: a double‐blind, placebo‐controlled study , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  C. Suphioglu.  What are the important allergens in grass pollen that are linked to human allergic disease? , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  H. Malling,et al.  Safety of allergen‐specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side‐effects during induction treatment , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[28]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[29]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[30]  R. Van Ree,et al.  How far can we simplify in vitro diagnostics for grass pollen allergy?: A study with 17 whole pollen extracts and purified natural and recombinant major allergens. , 1998, The Journal of allergy and clinical immunology.

[31]  M. Jacobson,et al.  Grass pollen immunotherapy: efficacy and safety during a 4‐year follow‐up study , 1995, Allergy.

[32]  H. Løwenstein,et al.  Group V allergens in grass pollens. II. Investigation of group V allergens in pollens from 10 grasses , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[33]  B. Rogala,et al.  Risks and benefits of allergen immunotherapy. , 2009, Expert opinion on drug safety.

[34]  W. Thomas,et al.  Recombinant allergens for immunotherapy , 2000 .